Oppenheimer raised the firm’s price target on HCA Healthcare to $390 from $345 and keeps an Outperform rating on the shares. The firm notes HCA issued robust Q2 results and significantly raised 2024 guidance, largely driven by strong volume trends and improved margin trends. Overall, Oppenheimer believes HCA continues to do an impressive job, consistently outperforming on growth and margin drivers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
Questions or Comments about the article? Write to editor@tipranks.com